Background: Guidelines for acute coronary syndrome recommend statins, β-blockers, angiotensin-converting-enzyme inhibitors or reninangiotensin system blockers, and antiplatelet agents for the secondary prevention of cardiovascular events. The aim was to examine associations between guideline recommended medications and fall-related hospitalizations and cardiovascular events in robust and frail older women. Methods: 2002-2011 surveys from the Australian Longitudinal Study on Women's Health linked with administrative hospital, pharmaceutical and death registry data (2003-mid-2011) were used. Eight hundred eighty-five women (82.7 ± 2.7 years, range 76-90) had prior admission for ischemic heart disease and ≥1 claims for any of the four medication classes. Four hundred thirteen (46.7%) were robust and 472 (53.3%) were frail. Fall-related admissions; cardiovascular event-related admissions or death; and cardiovascular death were recorded. Associations between each of the exposures and outcomes were analyzed using survival analyses with noncardiovascular death as a competing risk. Results: There were 192 fall-related admissions and 314 cardiovascular events including 82 deaths. Using four recommended classes (compared to using one) was associated with increased risks of fall-related admissions (hazard ratio [HR] = 2.57, 95% confidence interval [CI] = 1.24-5.33), but not with cardiovascular events (HR = 1.41, CI = 0.97-2.05) or cardiovascular death (HR = 0.68, CI = 0.35-1.34). Associations for fall-related admissions were stronger in frail participants (HR = 5.46, CI = 1.34-22.30) than robust (HR = 1.37, CI = 0.48-3.95). Conclusions: In older women with ischemic heart disease, the combination of the four recommended medication classes was associated with increased risk of falls, particularly among frail women, with no statistically significant gain in cardiovascular health. The risks of falls and consequential morbidity in women over 75 needs consideration when prescribing medications after myocardial infarction.
International clinical guidelines for acute coronary syndromes (ACS) recommend a combination of four medication classes to prevent further cardiovascular events such as heart attack, stroke, and death (1) (2) (3) . These four classes are statins, β-blockers, either angiotensinconverting-enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB), and antiplatelet agents. Although use of these medications is most common among older adults, there is little evidence for the safety and effectiveness of the combination of these medications in older people with multimorbidity, polypharmacy, and frailty (4) .
Frail older people are likely to use more medication than robust older people and can be at greater risk of medication-related harms (5) . Frailty is associated with pharmacokinetic changes (6) , which may further increase the risk of adverse events (4) . There are limited data on the use and impact of guideline recommended medications in frail compared with robust older women.
A systematic review suggested no clear association between antihypertensive drugs (including ACEI, β-blockers, diuretics, and calcium channel blockers) or aspirin and falls (7) . More recent studies among community-dwelling older adults produced conflicting results. ACEI and ARBs have been associated with a lower fall risk (8) , yet moderate (9) or high (10) doses of antihypertensives have been linked to a higher risk of injurious falls. Statin use has been associated with muscle weakness (11) and balance (12) , but not fractures (13) , while conflicting findings were reported for falls (12, 14) .
The aim of this study was to examine the effect of guideline recommended medications for ACS on fall-related admissions and cardiovascular events in older women with prior admissions for ischemic heart disease (IHD). We examined the total sample and separately for robust and frail older women.
Methods

Participants
The Australian Longitudinal Study on Women's Health is an ongoing study of factors affecting the health and wellbeing of three large population-based cohorts of women born in 1973-1978, 1946-1951, and 1921-1926 . Recruitment and data collection procedures for these cohorts have been described in detail elsewhere (15, 16) . In summary, in 1996, women were randomly selected from the national Medicare health insurance database which includes all citizens and permanent residents of Australia. The sample was reasonably representative of the general population of Australian women, although there was overrepresentation of Australia-born and university educated women (15) . Ethical clearance was obtained from the Universities of Newcastle and Queensland. All participants signed informed consent.
Data from the 1921-1926 cohort were used, which included 12,432 women in 1996. Participants have been re-surveyed every 3 years up to 2011. Analysis of attrition and comparisons with national data indicate that the cohort remains representative of the general population of surviving women of this age (17) . As pharmaceutical and hospital data were available from 2003 onward, the 2002 survey was taken as study baseline. Data were included from participants who returned the 2002 survey, lived in states for which hospital data were available, and had a hospital admission for IHD between January 1, 2003 and July 1, 2011 ( Figure 1 ). 
Index Admission for IHD
Fall-Related Admissions
The outcome fall-related admissions was defined as the first admission after the index date and before July 1, 2011 with: (i) a primary diagnosis or external cause for falls (W00-W15, W17-W19); (ii) a primary diagnosis for fracture; or (iii) a primary diagnosis for other injuries (S01-S99, T01-T14, T90-T98) if also a diagnosis for syncope/collapse (R29.6), tendency to fall (R55), or fall (W00-W15, W17-W19) was recorded.
Cardiovascular Events and Death
"Cardiovascular event" was defined as the first admission after the index date and before July 1, 2011 with a primary diagnosis for: angina (I20), myocardial infarction (I21-I23), cardiac arrest (I46), stroke (I60-I64), other cerebrovascular disease (I67-I69), aneurysm/ dissection (I71-I72), and arterial embolism/ thrombosis (I74). Date and cause of death were extracted from the National Death Registry. Deaths related to the listed cardiovascular events were classified as cardiovascular death and included as a cardiovascular event if this was the first event that occurred after the index event. All other causes of death were classified as noncardiovascular death.
Medication Use
The Pharmaceutical Benefits Scheme (PBS) subsidizes prescription medications for all Australian citizens and permanent residents (18) . Each prescription medication dispensed is recorded in the PBS administrative database using a PBS item number (specific for medication strength, dose form, and quantity) and date (Supplementary Table S1 ). Medication use was defined as having one or more of the medications dispensed after the index event and before the first outcome event or end of follow-up (ie, July 1, 2011). ACEI and ARB were counted as one class (ACEI-ARB). "Number of medication classes" was defined as the number of recommended medication classes that the participant had one or more claims for between the index event and end of follow-up, with one class as the reference category. Also, four dichotomous variables were created differentiating users and nonusers (reference category) of each of the four classes.
PBS data were used to derive the dichotomous "fall risk increasing drugs" (FRID) variable (19) , which indicates using at least one of the following medications between index event and end of follow-up (excluding statins, β-blockers, ACEI-ARB and antiplatelet agents): digitalis, anti-arrhythmics, nitrates, antihypertensives, diuretics, calcium-channel blockers, opioids, anti-epileptics, antiparkinson, antipsychotics, anxiolytics, sedatives/hypnotics, antidepressants, anti-vertigo, anticholinergics, hypoglycemics, antispasmodics, alphablockers, steroids, NSAID, anti-gout, adrenergics, cough suppressants, and antihistamines. 
Frailty
The Frail Scale was used to classify participants as "robust" (<3 markers) or "frail" (≥3 markers) based on presence of: >5% weight loss over 3 years, feeling fatigued, difficulty climbing stairs, difficulty walking 100 m and having ≥5 chronic conditions (20) . Markers were based on self-report at the last survey before the index event, and weight loss was calculated from weight reported since the previous survey. This scale was valid and responsive to changes in selfreported health in the original older cohort of this study (20) .
Sample Characteristics
Survey variables were measured at the last survey before the index event and included age, area of residence, level of education, body mass index, number of comorbidities (including doctor diagnosis of arthritis, diabetes, hypertension, stroke, lung disease, osteoporosis, and cancer), depression, physical activity ( 
Statistical Analyses
Sample characteristics were compared between those using one to three and four medication classes. A p-value of <.05 was considered statistically significant. All analyses were conducted with STATA version 13.1 (StataCorp LP. College Station, TX).
The association between medication use and risk of fall-related admissions, cardiovascular events and cardiovascular death were examined using competing risk regression models with robust standard errors, and reported as sub-HR with 95% confidence intervals (CI). Noncardiovascular death was used as the competing risk. For each of the outcomes, the survival time in days was calculated from the date of first prescription to the time of the first event, noncardiovascular death or end of the follow-up (June 30, 2011), whichever occurred first. Participants with one or more claims in the 3 months preceding the index event were classified as users from the date of index event.
The exposures "number of medication classes" and "users versus nonusers" were included as time-varying covariates. For "number of medication classes" this means that for participants who were dispenced a second class after a first class and before the outcome of interest occured, two records were created so that these participants were included in the analyses twice: first as a one class user with time to censoring (ie, the time of the first dispensing of the second class), then as a two classes user with time from first dispensing for the second class to the time of outcome. Additional records were created for three and four class users. When comparing users versus nonusers of each specific class, an extra record was created at the time of first dispensing for the class of interest. This approach allowed maximum use of the available data and standardized the start of follow-up for all participants at the time of the first dispensing for the first class.
All analyses were done using data for the total sample. To examine potential interaction with frailty status, the p-value for interaction was estimated by including the product term "number of medication classes" × frailty as a continuous variable to the model. Also, the model for "number of medication classes" was repeated for robust and frail participants separately. The models were run after adjustment for relevant covariates. Potential covariates were age, area of residence, level of education, BMI, number of comorbidities, depression, alcohol intake, physical function, smoking status, FRIDs, and frailty. Covariates were included in the model if they changed the log of the HR by more than 10%. This criterion was only reached by the FRID variable.
Preliminary analyses showed that 229 (24.9%) participants had missing values for at least one of the potential covariates. Apart from education, participants with and without missing values did not differ in terms of sample characteristics (Supplementary Table  S2 ). Multiple imputation by chained equations was used and 15 datasets created. Pooled results are presented based on Rubin's rules. Sensitivity analyses were performed including only participants with complete data to examine effects of imputation.
Results
A total of 916 participants had an index event, of whom 885 (96.6%) participants subsequently filled prescriptions for at least one guideline-recommended medication (Figure 1) . The average follow-up was 3.0 ± 2.5 years for fall-related admissions and 2.7 ± 2.5 years for cardiovascular events. Participants using all four classes were slightly younger (82.3 ± 2.6 years) than those using 1-3 classes (82.9 ± 2.7 years) (p ≤ .01, Table 1 ). Each class was used by over two-thirds of the sample (Table 2) . During follow-up, there were 257 (29.0%) fall-related admissions and 314 (35.5%) cardiovascular events including 82 (9.3%) cardiovascular deaths.
Use of all four medication classes was associated with a higher risk of fall-related admissions compared with one class (HR = 2.57, CI = 1.24-5.33) (Figure 2 , Table 3 ). This association existed in frail participants (HR = 5.46, CI = 1.34-22.30) but not in robust participants (HR = 1.37, CI = 0.48-3.95). No statistically significant association was found between number of medication classes used and cardiovascular events or deaths. The p-values for interaction between number of medication classes and frailty in the associations with fall-related admissions, cardiovascular events and cardiovascular deaths were 0.15, 0.74, and 0.99, respectively.
Analyses of the individual medication classes did not reveal any associations with fall-related admissions. Compared with nonusers, statin users had higher risks of cardiovascular events and lower risks of cardiovascular deaths (Table 3) . Antiplatelet users had higher risks of both cardiovascular events and deaths.
Similar results were obtained with the compelete case analyses (Supplementary Table S3 ).
Discussion
The results indicate that risks and benefits of guideline-recommended medications for ACS need to be considered differently in women over 75 years, especially in frail women. Whilst it was encouraging to see that guideline medications were being used, with 97% of women receiving at least one and 71% at least three of the recommended medication classes, almost all these women were exposed to potential risks of medication-related falls. Women receiving all four classes had a 2.6 times higher risk of fall-related hospitalizations compared with those receiving one class. In frail women, this risk increased to 5.5-fold. This presents considerable risk in terms of mortality and morbidity associated with falls severe enough to require hospitalization (23, 24) . As only about 10% of all falls in older women result in hospitalization (23) , the actual number of falls will have been underestimated as this study only documented falls which resulted in hospitalization.
While no statistically significant associations were found between any of the individual medication classes and fall-related admissions, the CIs were wide suggesting the study may have been underpowered. However, lack of associations between each medication class and fall-related admissions is consistent with findings from a study in a nationally representative sample of 4,961 U.S. older adults with hypertension (9). A systematic review suggested no association between β-blockers and fall risk (25) , but a protective effect of β-blockers on fracture risk has been suggested in other systematic reviews (26, 27) . For statins, our findings are consistent with a cohort study of 500 community-dwelling older adults (aged 70-90) and a randomized controlled trial comparing 20 mg of daily rosuvastatin with placebo in 17,802 men, which found no associations between statin use and risk of falls (12) and fractures (13) . But the findings are in contrast to secondary data-analyses of a randomized controlled trial comparing vitamin B with placebo in 2,407 ambulant older adults, which found that statin use reduced the fall risk (14) . As statins have been associated with both beneficial and harmful effects on multiple fall risk factors (eg, macular degeneration, cognitive decline, myopathy, and balance), an association between statin use and fall risk seems biologically plausible, while the beneficial and harmful effects may also cancel each other out.
Clinical trials of secondary prevention programs in coronary heart disease in unselected populations have shown small benefits in all-cause mortality (28) . Studies among 462 men with IHD and 4,655 men and women with myocardial infarction showed that using three or four classes was associated with lower risk of all-cause mortality compared with using none (29, 30 ). In the current study, the outcome included cardiovascular deaths only and adjustment was made for noncardiovascular deaths, whereas the other studies looked at all-cause mortality. The lower number of cardiovascular deaths and wide CI for the HR (HR = 0.68, CI = 0.35-1.34), suggest too few participants to detect a statistically significant association with number of medication classes. Another difference was that in the current Note: IQR = inter quartile range; SD = standard deviation. study, 97% of the women with the index event were subsequently dispensed at least one of the medication groups recommended by the guidelines and hence there were too few women with none of the medication classes to form a comparator group. The all-cause mortality rate in these 34 women was much higher (79.0%) than in those using one or more classes. The majority of these deaths were due to noncardiovascular causes (77.8%). Nonusers may have had other diseases or poor prognoses when hospitalized for IHD (31) .
The current results raise concerns about the safety of the recommended pharmaceutical treatment of ACS in older women, particularly among frailer women. While use of the four recommended medications increased the fall risk, little benefit was observed in this study on cardiovascular outcomes. As no differences were found in characteristics between the groups, the fall risk is unlikely to be explained by differences in health or lifestyle between those using all four medications compared with those using fewer medications. The increased risk associated with number of medication classes could reflect the increased fall risk associated with polypharmacy (32, 33) rather than the specific four medication classes prescribed for ACS. As no information was available on actual intake, effects of adherence, and dose could not be evaluated. The optimal combination of medications and doses to optimize cardiovascular health while minimizing the fall risk in frail older women needs further reappraisal.
An important strength of this study was that anticipated positive and negative effects of medication use were evaluated in the same cohort, which enables a balanced interpretation of the associated benefits and harms of treatment. Other strengths include the population-based origin of the sample to reflect the real-life effectiveness of the pharmaceutical management of women with IHD in the context of comorbidities and concurrent therapy, unlike clinical trials. Use of administrative data ensured continuous objective tracking of medication use and clinical outcomes. Selection bias was minimized by selecting participants with IHD. The medication variables were set up as time-dependent covariates to prevent immortal selection bias and immortal misclassification bias (34, 35) .
The following limitations need to be considered. The number of women with IHD may have been too small to detect small differences in outcomes, particularly between groups taking different medication classes, such as those expected in cardiovascular outcomes and death over short time periods. Covariates were carefully selected and only FRIDs met the criteria for confounding. However, sensitivity analyses with additional adjustments for age, smoking, BMI, and comorbidities only marginally affected the HRs and confidence intervals (data not shown) and would not change the interpretation of the results. Nonetheless, residual confounding cannot be ruled out. No information was available on severity of the index event. Participants with more severe index events may have been prescribed more medications. This could potentially explain the absence of a protective effect of medication use on cardiovascular outcomes. Hospitalizations for cardiovascular outcomes and falls are clinically important, but this study did not document events that did not require hospital admissions. The percentage of FRID users was high across all categories. Use of FRIDs was included as a covariate in models; however this may have insufficiently adjusted for confounding. Medication use was based on subsidized dispensed prescriptions and thus did not include nonsubsidized medications. Public subsidy covers all Australian citizens and residents, but for inexpensive over-the-counter medications, such as low dose aspirin, women may prefer to purchase these directly from a pharmacy. However, many women would also have been receiving clopidogrel, and misclassification due nonsubsidized use is likely to be limited. However, low dose aspirin could not be included and the CIs for the estimates for antiplatelet users were wide, only just including 1. It is therefore difficult to draw any conclusions from these results and further data are needed before any recommendations can be made. Finally, the sample included women with IHD and thus the findings cannot be generalized to samples with other characteristics. The prevalence of cardiovascular death in this sample was 9.3%. The median age at time of index event was 82-83 years. As expected based on differences in health (IHD vs general population) 1 year [AIHW] ), the prevalence of CVD mortality is higher in the current sample than in the general population of older Australian women (aged 85+): 9.3% versus 2.2%, respectively (36) .
In conclusion, these results raise concerns about the safety of the combined use of statins, β-blockers, ACEI-ARB, and antiplatelet agents for the treatment of ACS in older women. Particularly among frailer women, the combination of these four medication classes increased the fall risk while little benefit was observed in terms of cardiovascular outcomes.
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